Core Insights - BioRestorative Therapies, Inc. has received a provisional license from the New York State Department of Health for processing allogeneic donor tissue material, including stem cells, for medical research [1][3] - The expanded license allows the company to utilize its cGMP manufacturing capabilities for processing, banking, and distribution of clinical-grade allogeneic biologics [2][4] Company Overview - BioRestorative focuses on developing therapeutic products using adult stem cells, with core clinical programs targeting disc/spine disease and metabolic disorders [5] - The lead product, BRTX-100, is designed for non-surgical treatment of lumbosacral disc disorders and is currently in a Phase 2 clinical trial for chronic lower back pain [5] - The ThermoStem program aims to develop therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells [6] - The company also operates a BioCosmeceutical platform, offering products aimed at cosmetic improvements through cell-based secretome technology [7]
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health